Japan Biotech Develops 30-Minute Cure For Africa’s Sleeping Sickness
This article was originally published in PharmAsia News
Japanese biotech aRigen Pharmaceuticals says it has developed a fast-acting drug to treat the sleeping sickness that plagues Africa. The company conducted its research with the University of Tokyo on the fungus-based compound ascofuranone that interferes with an oxygen-supplying enzyme. Tests on mice show the drug kills parasites in 30 minutes, but Phase I human trials have not begun. aRigen plans to license development rights to a foreign company. (Click here for more - a subscription may be required
You may also be interested in...
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.
The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.
The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.